The role of stathmin expression in the differential diagnosis, prognosis, and potential treatment of ovarian sex cord-stromal tumors.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-08-30 DOI:10.1186/s13000-024-01541-x

Adam Šafanda, Michaela Kendall Bártů, Romana Michálková, Marián Švajdler, Tetiana Shatokhina, Jan Laco, Radoslav Matěj, Gábor Méhes, Jana Drozenová, Jitka Hausnerová, Zuzana Špůrková, Jozef Škarda, Mária Hácová, Monika Náležinská, Pavel Dundr, Kristýna Němejcová

{"title":"The role of stathmin expression in the differential diagnosis, prognosis, and potential treatment of ovarian sex cord-stromal tumors.","authors":"Adam Šafanda, Michaela Kendall Bártů, Romana Michálková, Marián Švajdler, Tetiana Shatokhina, Jan Laco, Radoslav Matěj, Gábor Méhes, Jana Drozenová, Jitka Hausnerová, Zuzana Špůrková, Jozef Škarda, Mária Hácová, Monika Náležinská, Pavel Dundr, Kristýna Němejcová","doi":"10.1186/s13000-024-01541-x","DOIUrl":null,"url":null,"abstract":"Background: Stathmin, a cytosolic microtubule-destabilizing phosphoprotein involved in the regulation of mitosis, is widely expressed in various malignancies and acts as an adverse prognostic factor. Our research analyzed its immunohistochemical expression on a large cohort of ovarian sex cord-stromal tumors, evaluating its potential utility in differential diagnosis, prognosis, and therapeutic application.Methods: We examined 390 cases of ovarian sex cord-stromal tumors including 281 adult granulosa cell tumors (AGCT), 5 juvenile granulosa cell tumors (JGCT), 33 Sertoli-Leydig cell tumors (SLCT), 50 fibromas/thecomas (F/T), 11 Leydig cell tumors/steroid cell tumors (LCT/SterCT), 5 sex-cord stromal tumors NOS (SCST-NOS), 3 Sertoli cell tumors (SCT), and 2 sclerosing stromal tumors (ScST). Immunohistochemical analysis was performed using TMAs.Results: Strong expression (> 50%) was observed in all cases of AGCT, JGCT, SLCT, SCST-NOS, SCT and 1 ScST. The other case of ScST exhibited mild expression (5-10%). The negative cases included exclusively F/T and LCT/SterCT, with F/T showing 24% of negative cases and LCT/SterCT comprising 64% of negative cases.Conclusion: The results of our study indicate that stathmin is neither a prognostic marker nor suitable for the differential diagnosis of challenging cases of ovarian sex cord-stromal tumors. However, its predictive value may be theoretically significant, as a decrease in stathmin expression potentialy influences response to chemotherapy treatment.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11363365/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13000-024-01541-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Stathmin, a cytosolic microtubule-destabilizing phosphoprotein involved in the regulation of mitosis, is widely expressed in various malignancies and acts as an adverse prognostic factor. Our research analyzed its immunohistochemical expression on a large cohort of ovarian sex cord-stromal tumors, evaluating its potential utility in differential diagnosis, prognosis, and therapeutic application.

Methods: We examined 390 cases of ovarian sex cord-stromal tumors including 281 adult granulosa cell tumors (AGCT), 5 juvenile granulosa cell tumors (JGCT), 33 Sertoli-Leydig cell tumors (SLCT), 50 fibromas/thecomas (F/T), 11 Leydig cell tumors/steroid cell tumors (LCT/SterCT), 5 sex-cord stromal tumors NOS (SCST-NOS), 3 Sertoli cell tumors (SCT), and 2 sclerosing stromal tumors (ScST). Immunohistochemical analysis was performed using TMAs.

Results: Strong expression (> 50%) was observed in all cases of AGCT, JGCT, SLCT, SCST-NOS, SCT and 1 ScST. The other case of ScST exhibited mild expression (5-10%). The negative cases included exclusively F/T and LCT/SterCT, with F/T showing 24% of negative cases and LCT/SterCT comprising 64% of negative cases.

Conclusion: The results of our study indicate that stathmin is neither a prognostic marker nor suitable for the differential diagnosis of challenging cases of ovarian sex cord-stromal tumors. However, its predictive value may be theoretically significant, as a decrease in stathmin expression potentialy influences response to chemotherapy treatment.

查看原文本刊更多论文

Stathmin表达在卵巢性索间质肿瘤的鉴别诊断、预后和潜在治疗中的作用。

背景：Stathmin是一种参与有丝分裂调控的细胞膜微管稳定磷蛋白，在各种恶性肿瘤中广泛表达，是一种不良预后因素。我们的研究分析了其在大量卵巢性索间质肿瘤中的免疫组化表达，评估了其在鉴别诊断、预后和治疗应用中的潜在作用：我们研究了 390 例卵巢性索-基质肿瘤，包括 281 例成人颗粒细胞瘤（AGCT）、5 例幼年颗粒细胞瘤（JGCT）、33 例绒毛膜-Leydig 细胞瘤（SLCT）、50 例纤维瘤/肉瘤、50个纤维瘤/肉瘤（F/T）、11个Leydig细胞瘤/类固醇细胞瘤（LCT/SterCT）、5个性索间质瘤NOS（SCST-NOS）、3个Sertoli细胞瘤（SCT）和2个硬化性间质瘤（ScST）。使用 TMA 进行了免疫组化分析：在所有 AGCT、JGCT、SLCT、SCST-NOS、SCT 和 1 例 ScST 中均观察到强表达（> 50%）。另一例 ScST 表现为轻度表达（5%-10%）。阴性病例仅包括 F/T 和 LCT/SterCT，其中 F/T 占阴性病例的 24%，LCT/SterCT 占阴性病例的 64%：我们的研究结果表明，stathmin既不是预后标志物，也不适合用于卵巢性索间质肿瘤疑难病例的鉴别诊断。然而，它的预测价值在理论上可能是有意义的，因为stathmin表达的减少可能会影响对化疗治疗的反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464